PMID- 35183749
OWN - NLM
STAT- MEDLINE
DCOM- 20220622
LR  - 20230919
IS  - 1469-0691 (Electronic)
IS  - 1198-743X (Print)
IS  - 1198-743X (Linking)
VI  - 28
IP  - 7
DP  - 2022 Jul
TI  - Variability of interferon-gamma release assays in people at high risk of tuberculosis 
      infection or progression to tuberculosis disease living in the United States.
PG  - 1023.e1-1023.e7
LID - S1198-743X(22)00094-5 [pii]
LID - 10.1016/j.cmi.2022.02.020 [doi]
AB  - OBJECTIVES: Interferon-gamma release assays, including T-SPOT.TB (TSPOT) and 
      QuantiFERON Gold In-Tube (QFT), are important diagnostic tools for tuberculosis 
      infection, but little work has been done to study the performance of these tests 
      in populations prioritized for tuberculosis testing in the United States, 
      especially those other than health care personnel. METHODS: Participants were 
      enrolled as part of a large, prospective cohort of people at high risk of 
      tuberculosis infection or progression to tuberculosis disease. All participants 
      were administered a tuberculin skin test, TSPOT, and QFT test. A subset of 
      participants had their QFT (n = 919) and TSPOT (n = 885) tests repeated when they 
      returned to get their tuberculin skin test read 2 to 3 days later (repeat study). 
      A total of 531 participants had a TSPOT performed twice on the same sample taken 
      at the same time (split study). RESULTS: The QFT repeat test interpretations were 
      discordant (one test positive and the other negative) for 6.4% of participants 
      (59 of 919), and the TSPOT tests were discordant for 60 of 885 participants in 
      the repeat study (6.8%) and 41 of 531 participants in the split study (7.7%). 
      There was a high degree of variability in the quantitative test results for both 
      QFT and TSPOT, and discordance was not associated with both test results being 
      near the established cut-offs. Furthermore, the proportion of discordance was 
      similar when comparing participants in both the TSPOT repeat and TSPOT split 
      studies. DISCUSSION: Both QFT and TSPOT were 6% to 8% discordant. The results 
      should be interpreted with caution, particularly when seeing a conversion or 
      reversion in serial testing.
CI  - Published by Elsevier Ltd.
FAU - Winglee, Kathryn
AU  - Winglee K
AD  - Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 
      Atlanta, GA, USA. Electronic address: nrf1@cdc.gov.
FAU - Hill, Andrew N
AU  - Hill AN
AD  - Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 
      Atlanta, GA, USA.
FAU - Belknap, Robert
AU  - Belknap R
AD  - Public Health Institute at Denver Health, Denver, CO, USA.
FAU - Stout, Jason E
AU  - Stout JE
AD  - Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
FAU - Ayers, Tracy L
AU  - Ayers TL
AD  - Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, 
      Atlanta, GA, USA.
LA  - eng
GR  - CC999999/ImCDC/Intramural CDC HHS/United States
PT  - Journal Article
DEP - 20220218
PL  - England
TA  - Clin Microbiol Infect
JT  - Clinical microbiology and infection : the official publication of the European 
      Society of Clinical Microbiology and Infectious Diseases
JID - 9516420
SB  - IM
MH  - Humans
MH  - Interferon-gamma Release Tests/methods
MH  - *Latent Tuberculosis/diagnosis
MH  - Prospective Studies
MH  - Tuberculin Test/methods
MH  - *Tuberculosis/diagnosis
MH  - United States/epidemiology
PMC - PMC10065409
MID - NIHMS1872422
OTO - NOTNLM
OT  - Epidemiology
OT  - Interferon-gamma release assay
OT  - QuantiFERON
OT  - T-SPOT.TB
OT  - Tuberculosis
EDAT- 2022/02/21 06:00
MHDA- 2022/06/23 06:00
PMCR- 2023/07/01
CRDT- 2022/02/20 20:31
PHST- 2021/11/19 00:00 [received]
PHST- 2022/01/25 00:00 [revised]
PHST- 2022/02/10 00:00 [accepted]
PHST- 2022/02/21 06:00 [pubmed]
PHST- 2022/06/23 06:00 [medline]
PHST- 2022/02/20 20:31 [entrez]
PHST- 2023/07/01 00:00 [pmc-release]
AID - S1198-743X(22)00094-5 [pii]
AID - 10.1016/j.cmi.2022.02.020 [doi]
PST - ppublish
SO  - Clin Microbiol Infect. 2022 Jul;28(7):1023.e1-1023.e7. doi: 
      10.1016/j.cmi.2022.02.020. Epub 2022 Feb 18.